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Abstract
Background: Considerable variation exists in diagnostic tests used for local response evaluation after
chemoradiation in patients with advanced oropharyngeal cancer. The yield of invasive examination under general
anesthesia (EUA) with biopsies in all patients is low and it may induce substantial morbidity. We explored four
response evaluation strategies to detect local residual disease in terms of diagnostic accuracy and cost-
effectiveness.
Methods: We built a decision-analytic model using trial data of forty-six patients and scientific literature. We
estimated for four strategies the proportion of correct diagnoses, costs concerning diagnostic instruments and the
proportion of unnecessary EUA indications. Besides a reference strategy, i.e. EUA for all patients, we considered
three imaging strategies consisting of 18FDG-PET-CT, diffusion-weighted MRI (DW-MRI), or both 18FDG-PET-CT and
DW-MRI followed by EUA after a positive test. The impact of uncertainty was assessed in sensitivity analyses.
Results: The EUA strategy led to 96% correct diagnoses. Expected costs were €468 per patient whereas 89% of EUA
indications were unnecessary. The DW-MRI strategy was the least costly strategy, but also led to the lowest
proportion of correct diagnoses, i.e. 93%. The PET-CT strategy and combined imaging strategy were dominated by
the EUA strategy due to respectively a smaller or equal proportion of correct diagnoses, at higher costs. However,
the combination of PET-CT and DW-MRI had the highest sensitivity. All imaging strategies considerably reduced
(unnecessary) EUA indications and its associated burden compared to the EUA strategy.
Conclusions: Because the combined PET-CT and DW-MRI strategy costs only an additional €927 per patient, it is
preferred over immediate EUA since it reaches the same diagnostic accuracy in detecting local residual disease
while leading to substantially less unnecessary EUA indications. However, if healthcare resources are limited,
DW-MRI is the strategy of choice because of lower costs while still providing a large reduction in unnecessary
EUA indications.
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Background
Patients with resectable advanced staged oropharyngeal
squamous cell carcinoma (OPSCC) are often treated
with chemoradiation (CRT) in order to preserve organ
function and quality of life. Low residual and recurrent
tumour rates indicate that CRT is an adequate treatment
option [1]. Still, thorough follow-up is warranted to
detect residual tumour, which can be successfully treated
with salvage surgery if detected early. Previous research
has shown that early detection of residual tumour is
associated with more favourable survival probabilities
and better local control [1, 2]. Thus, timely detection of
residual tumour is essential.
A Dutch survey showed that there is considerable
variation in response evaluation after CRT, especially in
the diagnostic tests performed [3]. Tests that are used
are examination under general anesthesia with taking of
biopsies (EUA), computed tomography (CT), magnetic
resonance imaging (MRI) and 18F–fluorodeoxy-glucose
positron emission tomography combined with CT (18F–
FDG-PET-CT). EUA is considered to be the most reli-
able procedure to detect residual disease but is an inva-
sive procedure during which biopsies are taken in areas
treated with CRT. Besides the risk of side-effects such as
pain, inflammation and wound healing problems, there
is also the possibility of sampling error leading to false-
negative results [1]. Furthermore, EUA has considerable
impact on scarce resources because hospital stay and
operating facilities are required.
In contrast to EUA, imaging tests are not invasive. How-
ever, conventional CT and MRI may not be suitable be-
cause postradiation effects, e.g. fibrosis and necrosis [4],
may hamper accurate interpretation of the images. More
advanced tests such as 18F–FDG-PET-CT and diffusion-
weighted MRI (DW-MRI) may be more suitable options.
These tests do not only assess if any anatomical residual
mass is present, but also determine the metabolic activity
and cell density, respectively, of the tumour.
PET-CT and DW-MRI cannot completely replace EUA
because pathological confirmation is required before
further treatment. Nevertheless, they could be used to
select those patients with a high risk of residual disease
for further diagnostic workup with EUA. This would
reduce the number of patients that have to undergo
futile invasive diagnostic procedures. Furthermore, the
imaging results provide the opportunity to guide biopsy
procedures, thereby possibly reducing sampling error.
Besides these advantages for patients, imaging to select
patients for EUA might also lead to cost reductions.
Therefore, this study aimed to assess the effects and
costs of four response evaluation strategies to detect
local residual disease, namely EUA for all patients, PET-
CT-based selection for EUA, DW-MRI-based selection
for EUA and a combination of PET-CT and DW-MRI to
select for EUA. All analyses were conducted using a
decision-analytic model based on trial data of forty-six
patients and scientific literature.
Methods
Strategies
We developed a decision-analytic model to evaluate the
effects and costs of four strategies for local response
evaluation in patients with OPSCC who underwent
CRT. In the first strategy under consideration, i.e. the
reference strategy, all patients undergo EUA 3 months
after completion of CRT for response evaluation. EUA is
considered positive if histopathological proof of viable
cancer has been found in the biopsy. The indication for
EUA is considered unnecessary if 6 months of follow-up
after response evaluation did not show residual disease.
In the three other strategies, response evaluation is
performed by either PET-CT (strategy 2), DW-MRI
(strategy 3) or a combination of PET-CT and DW-MRI
(strategy 4). Only patients with a positive imaging test
are referred to EUA. In strategy 4, patients are referred
to EUA based on a combined assessment by a radiologist
and nuclear medicine physician. The four strategies are
depicted by decision trees in Fig. 1. Each end node
reflects the diagnostic status of a patient who followed
that specific branch as well as the associated costs.
Data
Costs of the different diagnostic instruments were based
on official tariff lists [5]. As shown in Table 1, combined
PET-CT and DW-MRI was with 1313 Euros the most
expensive test. Test characteristics were obtained from a
prospective trial (2012–2014) in which patients with
advanced but resectable OPSCC who underwent CRT
were subjected to PET-CT, DW-MRI and EUA for re-
sponse evaluation 3 months after end of CRT (Dutch Trial
Register: NTR4111/NL39181.000.11). Patient and tumour
characteristics are summarized in Table 2. PET-CT and
DW-MRI images were interpreted by respectively two
nuclear medicine physicians (OH, EC) and two radiologists
(JC, PG). For PET-CT, we requested the observers indi-
vidually to score the PET-CT using the Hopkins criteria (a
5-point scale in which scores 1, 2 and 3 are considered
negative for tumour and scores 4 and 5 are considered
positive) [6]. DW-MRI observers scored signal intensity on
b1000 images and the corresponding ADC-map. A re-
sidual mass was considered ‘suspicious for residual disease’
if increased signal intensity on the b1000 images was
present, in an area of contrast-enhancement on post-
contrast T1WI and corresponding to low ADC-values. For
DW-MRI, we requested the observers individually to clas-
sify the MRI-examinations using a dichotomous system,
i.e. suspicious for a local residue or not, based on signal in-
tensity of the DW-images. In case readings were
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discrepant, consensus was reached between the observers
of either PET-CT or DW-MRI. For strategy 4, combined
reading of PET-CT and DW-MRI with visual correlation
by a radiologist and nuclear medicine physician was
performed in all patients with discrepancies between
the scoring of the two modalities. In total, 46 patients
were included of whom five (11%) had residual
tumour. Test characteristics of each diagnostic test are
shown in Table 2. Sensitivities were 60% or higher,
with the combined PET-CT and DW-MRI strategy
having the highest sensitivity. Specificity was lowest
for PET-CT with 83%.
Analyses
Using the decision trees, we calculated the expected
health effects of each response evaluation strategy, i.e.
the expected proportion of correctly diagnosed patients
(true positives and true negatives). Based on the costs of
each diagnostic instrument, the average costs accumu-
lated by a patient when following a specific branch in
the decision tree were estimated. Subsequently, for each
branch costs were multiplied by the probability that a
patient will follow this branch. Summing up the ex-
pected costs of each branch of the decision tree results
in the overall expected costs for that strategy. In
addition, the number of EUA indications as well as the
number of unnecessary EUA indications per response
evaluation strategy were calculated. It was not possible
to correctly estimate quality-adjusted life-years in this
study. As an alternative we estimated the costs per true-
positive case for the different strategies.
Sensitivity analyses
Due to the small sample size of this trial, we repeated the
base-case analysis using test characteristics based on the
literature. Sensitivity and specificity for PET-CT and DW-
MRI were derived from respectively a systematic review
by Gupta et al. (2011) [7] and the study of Vaid et al.
(2017) [8]. Test characteristics for EUA and combined
PET-CT and DW-MRI are not reported in the literature.
We further explored the impact of uncertainty regard-
ing the test characteristics of the diagnostic instruments
in univariate sensitivity analyses in which we increased
and decreased the sensitivity and specificity of each
instrument with 10% (absolute change). In the strategies
in which a positive imaging test was followed by EUA, only
the test characteristics of the imaging test were varied.
In addition, in clinical practice a positive EUA is usu-
ally followed by MRI and PET-CT to assess if surgical
intervention is feasible and if any distant metastases are
present, respectively. Therefore, in a sensitivity analysis
we included the costs of these additional tests in the
EUA strategy. Similarly, we added costs of an MRI or
whole body PET-CT (in case of a positive EUA) to those
Fig. 1 Decision trees of all evaluated strategies namely (a) EUA for
all patients, (b) PET-CT prior to EUA, (c) DW-MRI prior to EUA and (d)
PET-CT as well as DW-MRI prior to EUA. The end node depicts the
diagnostic status of the patient, i.e. true positive (TP), false negative
(FN), false positive (FP) or true negative (TN), as well as the costs
associated with that specific branch
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of the “head and neck” PET-CT and DW-MRI, respect-
ively. Finally, we assessed the impact of uncertainty
surrounding the prevalence of residual tumour by in-




The proportion of correctly diagnosed patients and the
expected costs per patient for each strategy are shown in
Table 3. The combined PET-CT and DW-MRI strategy
and the EUA strategy led to the highest proportion of
correctly diagnosed patients, i.e. 96%. However, the
expected costs of the EUA strategy were 927 Euros per
patient lower than those of the combined PET-CT and
DW-MRI strategy. The strategy with DW-MRI led to
the lowest expected costs per patient but also to the
lowest proportion of correct diagnoses. The PET-CT
strategy and the combined PET-CT and DW-MRI strat-
egy were dominated by the EUA strategy because these
strategies led to a smaller or equal proportion of correct
diagnoses, at higher costs.
Number of EUA indications and missed residual disease
Figure 2 shows the proportion of correct diagnoses as
well as the proportion of unnecessary EUA indications
per strategy. All imaging strategies led to a considerably
lower proportion of unnecessary EUA indications com-
pared to the EUA strategy. The combined PET-CT and
DW-MRI strategy led to the lowest proportion of
unnecessary EUA indications, i.e. 38%.
In Fig. 3, the total number of EUA indications, the num-
ber of unnecessary EUA indications and the expected
costs per patient are shown for 1000 patients. In the EUA
strategy, all patients underwent EUA, of which 891 indica-
tions were unnecessary. All imaging strategies substan-
tially reduced the number of required EUAs as well as the
number of unnecessary EUA indications. The DW-MRI
required the lowest number of EUAs, i.e. 109 EUAs of
which 43 indications were unnecessary. However, this
strategy also had the highest number of missed re-
sidual disease. Please note that the combined PET-CT
and DW-MRI required 65 additional EUAs compared
to the DW-MRI strategy, but a slightly lower proportion
of these EUA indications was unnecessary.
The costs per true-positive case were for EUA 7175
Euros, for PET-CT 24,058 Euros, for DW-MRI 7588
Euros and for combined PET-CT and DW-MRI 21,387
Euros. Although EUA and DW-MRI are much cheaper,
they detect less recurrences than PET-CT leading to
delayed salvage treatment with potentially poorer
outcome. The addition of DW-MRI to PET-CT lowered
the costs per true-positive case.
Univariate sensitivity analyses
When the test characteristics of DW-MRI were based
on the literature, the proportion of correct diagnoses
increased from 0.93 to 0.95. On the other hand, also the
expected costs and proportion of unnecessary EUA indi-
cations increased. For the PET-CT strategy, the propor-
tion of correct diagnoses remained 0.95 whereas the
expected costs and proportion of unnecessary EUA indi-
cations decreased when we based the test characteristics
on the literature.
In the majority of sensitivity analyses in which we var-
ied test characteristics, additional testing after a positive
EUA and the prevalence of residual disease, the ordering
of the strategies based on the proportion of correct diag-
noses, expected costs and proportion of unnecessary
EUA indications did not change, as shown in Table 3.
Only in the analysis in which the specificity of the diag-
nostic instruments was lowered with 10%, the ordering
of the strategies changed; the EUA strategy led to the
lowest proportion of correct diagnoses.
Discussion
This study explored the cost-effectiveness of four strat-
egies used for response evaluation to detect local re-
sidual disease after CRT in patients with advanced
staged OPSCC. In the EUA strategy, i.e. the reference
Table 1 Test characteristics and costs of the diagnostic instruments for response evaluation. In the base-case analysis, trial-reported
test characteristics were used









EUA 60 [14.7–94.7] 100 [91.4–100.0] 100.0 [29.2–100.0] 95.3 [84.2–99.4] * * 468
PET-CT 75 [19.4–99.4] 83 [67.9–92.8] 30.0 [6.7–65.2] 97.1 [85.1–99.9] 79.9a 87.5a 1067
DW-MRI 60 [14.7–94.7] 95 [83.5–99.4] 60.0 [14.7–94.7] 95.1 [83.5–99.4] 89.0b 86.0b 246
Combined PET-CT and DW-MRI 100 [39.8–100.0] 93 [80.1–98.5] 57.1 [18.4–90.1] 100.0 [90.7–100.0] * * 1313
*Test characteristics for this diagnostic instrument are not reported in the literature
aBased on the systematic review of Gupta et al. (2011) [7]
bBased on the study of Vaid et al. (2017) [8]
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strategy, 96% of patients were correctly diagnosed.
Expected costs were 468 Euros at the expense of 89%
unnecessary EUA indications. The DW-MRI strategy
was with 297 Euros the least costly strategy. However,
this strategy also led to the lowest proportion of correct
diagnoses, i.e. 93%. The PET-CT strategy and the com-
bined PET-CT and DW-MRI strategy were dominated
by the EUA strategy due to a smaller or equal propor-
tion of correct diagnoses, at higher costs. All imaging
strategies considerably reduced the number of EUA indi-
cations and unnecessary EUA indications compared to
the EUA strategy.
Based on our model results, the combined PET-CT
and DW-MRI strategy is preferred over the EUA strat-
egy. This strategy has the same diagnostic accuracy as
immediate EUA while considerably reducing the number
of EUA indications as well as unnecessary EUA indica-
tions. On the other hand, the combined imaging strategy
costs an additional 927 Euros. However, only around
220 patients are diagnosed each year with advanced
OPSCC in the Netherlands [10]. Thus, these additional
costs are negligible on a society level. Furthermore, if all
220 patients were evaluated based on the combined
imaging strategy, only 38 EUAs are indicated of which
14 would be unnecessary. When the EUA strategy would
be used for response evaluation, 220 EUAs are indicated
of which 196 would be unnecessary.
When healthcare resources are limited, our study
suggests that DW-MRI prior to EUA is the strategy of
choice. This strategy is less costly than both the com-
bined PET-CT and DW-MRI strategy and EUA strategy.
Furthermore, it has a lower impact on scarce resources
such as hospital stay compared to immediate EUA.
Moreover, fewer patients are exposed to invasive EUA
and of the EUA indications, a lower proportion is un-
necessary. However, the proportion of correct diagnoses
is lower than in the EUA strategy. This difference is
caused by a higher proportion of false-negative test
results meaning that residual tumour is missed.
Besides decreasing the number of unnecessary EUA
indications, another possible advantage of imaging is that
the results of the imaging test can be used to guide the
biopsy taking. This may increase the sensitivity of EUA.
As the surgeons in the trial were not blinded to the im-
aging results, it may be possible that the sensitivity of
EUA without prior imaging is overestimated. We assessed
the impact of this in sensitivity analyses by assuming a
10% lower sensitivity in the EUA strategy. This changed
the ordering of the strategies; the combined PET-CT and
DW-MRI strategy became the strategy with most correct
diagnoses. Nevertheless, EUA detected only 60% of the
residual tumours, questioning the degree of bias.
The test characteristics of PET-CT and DW-MRI were
based on a trial in which all patients received PET-CT,
DW-MRI and EUA 3 months after CRT. Timing is an
important determinant of these test characteristics. If
the test is conducted too soon after treatment, post-
radiation effects can lead to a false-positive test. Also
false-negative test results are possible because tumour
cells have not yet reached a detectable size. On the other
hand, early diagnosis of residual disease increases treat-
ment success of salvage surgery [11]. A study indicated
that DW-MRI may be used for response evaluation 3
Table 2 Patient and tumour characteristics




Mean age at diagnosis, years (range) 60.4 (44–71)
Oropharyngeal subsite
Base of tongue 22 (47.8%)
Tonsil 19 (41.3%)


















Never (0–5 pack years) 9 (19.6%)
Moderate (6–24 pack years) 8 (17.4%)
Heavy (>24 pack years) 29 (63.0%)
Alcohol consumption
Never (0) 3 (6.5%)
Moderate (1–149 unit years) 25 (54.3%)
Heavy (>149 unit years) 18 (39.1%)
Smoking was defined in pack years (1 pack year = 20 cigarettes a day
during 1 year)
Alcohol consumption was defined in unit years (1 unit year = one alcohol-
containing consumption a day during 1 year)
Abbreviations: CRT chemoradiotherapy, HPV Human papillomavirus, no number,
nos not otherwise specified
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Table 3 Expected proportion of correctly classified patients, expected costs per patient and proportion of unnecessary EUA
indications per strategy
Strategy Expected proportion of
correctly classified patients





EUA 0.96 468 7175 0.89
PET-CT 0.94 1177 24,058 0.65
DW-MRI 0.93 297 7588 0.40
Combined PET-CT and DW-MRI 0.96 1395 21,387 0.38
Test characteristics based on the literature
PET-CT 0.94 1160 22,264 0.56
DW-MRI 0.95 350 6025 0.56
Sensitivity +10%
EUA 0.97 468 6150 0.89
PET-CT 0.96 1207 18,352 0.60
DW-MRI 0.94 302 6615 0.36
Combined PET-CT and DW-MRIa 0.96 1395 21,387 0.38
Specificity +10%
EUA 0.96 468 7175 0.89
PET-CT 0.94 1135 23,205 0.44
DW-MRI 0.93 277 7068 0
Combined PET-CT and DW-MRI 0.96 1364 20,919 0
Sensitivity −10%
EUA 0.95 468 8610 0.89
PET-CT 0.93 1172 27,639 0.68
DW-MRI 0.92 292 8950 0.44
Combined PET-CT and DW-MRI 0.95 1390 23,677 0.40
Specificity −10%
EUA 0.87 468 7175 0.89
PET-CT 0.94 1218 24,910 0.75
DW-MRI 0.93 339 8654 0.67
Combined PET-CT and DW-MRI 0.96 1437 22,027 0.59
EUA followed by additional tests
EUA 0.96 574 8799 0.89
PET-CT 0.94 1189 24,304 0.65
DW-MRI 0.93 351 8966 0.40
Increasing the prevalence of residual disease
EUA 0.94 9834 5199 0.85
PET-CT 0.92 10,554 17,599 0.56
DW-MRI 0.90 9673 5696 0.32
Combined PET-CT and DW-MRI 0.94 10,778 15,697 0.29
Decreasing the prevalence of residual disease
EUA 0.98 7290 15,598 0.95
PET-CT 0.97 7982 51,592 0.81
DW-MRI 0.97 7103 15,655 0.61
Combined PET-CT and DW-MRI 0.98 8191 45,645 0.58
aSensitivity was 100% in base-case analysis
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weeks after CRT [12]. The optimal timing of imaging
has still to be determined, which might influence test
characteristics.
Furthermore, DW-MRI is a relative new imaging tech-
nique within oncological applications and therefore, little
experience is gained with DW-MRI in the post-treatment
evaluation so far. Besides, DW-imaging is susceptible to
artefacts, particularly in the inhomogeneous head and
neck area which contains a variety of tissues. Also, geo-
metrical distortions due to interfaces between soft tissue
and air or bone can occur. Although DW-MRI is not yet
an established technique for response evaluation, this early
assessment of the expected health effects and costs
provides more insight in the potential of DW-MRI as a
response evaluation strategy. We showed that DW-MRI is
the strategy of choice when combined with PET-CT.
However, a response evaluation strategy solely based on
DW-MRI followed by EUA in individuals with a positive
imaging test is only preferred in settings with limited
health care resources. Nevertheless, radiologists are still in
the learning curve concerning post-treatment evaluation
of DW-MRI. With more training and feedback, DW-MRI
is expected to obtain a higher accuracy. The impact of
increased sensitivity was assessed in sensitivity analyses,
but conclusions did not change.
Another emerging technique for response evaluation is
PET-MRI. This technique combines the often comple-
mentary data from PET and MRI and could lead to im-
proved anatomic localisation of focal uptake compared to
PET-CT [13]. This could potentially decrease the number
of false-positive test outcomes and as a consequence,
reduce the number of unnecessary EUA indications.
The trial included only 46 patients of whom five were
diagnosed with residual disease. Due to this small sample
size, there was a fair amount of uncertainty regarding test
characteristics and the prevalence of residual disease. Re-
peating the base-case analysis using test characteristics de-
rived from the literature did not change our conclusion.
Furthermore, our residual primary tumour rate of 11%
was in agreement with the results of Moeller et al. (2009)
[14]. On the other hand, Van den Broek et al. (2006) re-
ported a residual primary tumour rate of 7% [1]. We have
addressed this issue by varying the prevalence of residual
disease in one-way sensitivity analyses. However, the or-
dering of the strategies based on correct diagnoses, costs
and unnecessary EUA indications did not change.
In this cohort of patients, the residual primary tumour
rate was only 11%. To improve the yield of routine
response evaluation, only patients with high risk factors
should undergo this diagnostic procedure. Risk factors
which can be used to select patients include T-stage
[15], HPV (human papilloma virus) status [16, 17] and
pre-treatment metabolic tumour volume [18].
We did not differentiate between HPV-related and HPV-
unrelated tumours. For HPV-related tumours, a lower
residual disease rate is observed which is probably due to
higher responsiveness to chemoradiation [19, 20]. However,
it is unclear whether HPV-related tumours have the same
probability of being detected as HPV-unrelated tumours. In
this study, 44% of the tumours were HPV positive whereas
Fig. 3 Total number of EUA indications, number of unnecessary EUA
indications and expected costs per patient per strategy for 1000 patients
Fig. 2 Proportion of correct diagnoses and unnecessary EUA
indications per strategy
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all the patients with residual disease had a HPV negative
tumour. Nevertheless, the small sample size precludes
definite conclusions regarding differences in detection.
Outcomes of this study were the proportion of
correctly diagnosed patients, costs concerning diagnostic
instruments and the number of unnecessary EUA indica-
tions. This means that health benefits, i.e. the proportion
of correct diagnoses, and treatment burden, i.e. unneces-
sary EUA indications, were evaluated separately. More-
over, not all health benefits and treatment burden were
captured in these outcomes. For example, declined
survival probabilities due to false-negative test results as
well as side-effects of EUA were not taken into account.
Outcomes that encompass all health benefits and treat-
ment burden such as quality-adjusted life-years (QALYs)
would therefore be preferable. Comparing costs per
QALY would lead to a more comprehensive evaluation
of the response evaluation strategies. However, it was
not possible to calculate QALYs due to the trial design.
Patients in the trial were subjected to all tests for
response evaluation meaning that residual disease which
may be missed by one test (false-negative) could be
detected by one of the other tests. If patients would be
subjected to only one test, as in the strategies evaluated
in this study, patients with false-negative test results
would have become symptomatically detected at a later
point of time. Since earlier detection leads to improved
survival probabilities [1, 2], it was not possible to cor-
rectly estimate QALYs. As an alternative, we calculated
costs per true-positive case for the different strategies.
We hypothesize that the ordering of strategies would
not change when the evaluation was based on costs per
QALY. A strategy using an instrument with a high sensi-
tivity and few (unnecessary) EUA indications would be
favoured because this strategy would lead to low rates of
missed residual disease and low treatment burden. This
means that the combined PET-CT and DW-MRI strategy
would still be the strategy of choice. To assess this hypoth-
esis, future studies should include costs per QALY.
To our knowledge, few studies have assessed the cost-
effectiveness of response evaluation in patients with head
and neck cancer treated with CRT. Two studies compared
a strategy of PET-CT scanning prior to neck dissection
and up-front neck dissection for all patients. These studies
showed that the imaging strategy was more cost-effective
[9, 21]. Although these studies did not compare imaging
to EUA, they also indicate that imaging can be more cost-
effective than more invasive strategies.
In clinical practice, PET-CT can be used for response
evaluation at the primary site and neck and to detect
distant metastases simultaneously. Previous studies have
shown that PET-CT is cost-effective for response evalu-
ation after (chemo)radiation of the pretreatment ad-
vanced stage positive neck when only patients with a
PET-CT positive neck underwent neck dissection com-
pared to planned neck dissection in all patients [21, 22].
Moreover, pretreatment screening for distant metastases
using PET-CT appeared also to be cost-effective [23].
These evaluations by PET-CT add to the cost-effectiveness
of response evaluation of the primary site as reported in
the present study. For DW-MRI no data on cost-
effectiveness in response evaluation of neck disease is
available. Also for response evaluation of advanced nodal
neck disease the combination of PET-CT and DW-MRI
seems to have the highest sensitivity and specificity [24].
Results of cost-effectiveness studies can be used for
the development of a guideline for response evaluation
in patients with OPSCC. The need for such a guideline
is underlined by a previous study showing that there is
substantial variation in the diagnostic tests used for
response evaluation [3]. By including studies on cost-
effectiveness in the guideline development process,
guideline recommendations will not only be based on the
most effective strategy, but on the most cost-effective
strategy. This will lead to more sensible use of scarce
healthcare resources. This is the first cost-effectiveness
study evaluating different response evaluation strategies.
However, there was considerable uncertainty regarding
important model parameters due to the small sample size
of the trial. Additional studies, preferably based on trials
with a larger sample size, are required to provide a
comprehensive evidence base for guideline development.
Conclusions
This study suggests that combined PET-CT and DW-MRI
is the strategy of choice for local response evaluation. It is
preferred over immediate EUA since it costs only an add-
itional €927 while reaching the same diagnostic accuracy
and leading to substantially less unnecessary EUA indica-
tions and its associated burden. However, if healthcare
resources are limited, DW-MRI is the preferred strategy
because of lower costs while maintaining the number of
unnecessary EUA indications low.
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